Clinical biochemistry最新文献

{"title":"Multi-institution comparison of whole blood potassium hemolysis rates","authors":"Christopher Farnsworth ,&nbsp;Jianbo Yang ,&nbsp;Robert Maynard ,&nbsp;Heather M. Stieglitz","doi":"10.1016/j.clinbiochem.2025.110955","DOIUrl":"10.1016/j.clinbiochem.2025.110955","url":null,"abstract":"<div><h3>Introduction</h3><div>Hemolysis causes falsely elevated potassium results and if undetected, can lead to misidentification of hypokalemia or hyperkalemia causing delayed or inappropriate treatment. The prevalence of hemolysis in whole blood samples submitted for potassium or blood gas analysis remains unknown due to historical limitations in blood gas analyzer hemolysis detection. This study aimed to compare hemolysis rates in whole blood potassium samples measured by blood gas analyzers at four different academic medical centers. Further, we compared rates among differing blood sources and hospital settings, and potassium results among different hemolysis flags.</div></div><div><h3>Materials and methods</h3><div>Potassium results and hemolysis flags measured on the GEM Premier 7000 at four different academic medical centers were compiled for six months at each location.</div></div><div><h3>Results</h3><div>A total of 37,944 samples with hemolysis flags were obtained from four academic medical centers with an overall hemolysis rate of 10.0 % (hemolysis flags corresponding to &gt; 50 mg/dL plasma free hemoglobin). Hemolysis rates varied by institution ranging from 9.2-14.6 %. Hemolysis rates were similar between arterial (8.6 %) and venous (10.6 %) samples but were substantially higher for capillary (17.7 %) samples. Samples collected in the emergency department showed greater hemolysis rates (17 %) compared to those samples originating in intensive care units (8.1 %) and all other (10.2 %) departments.</div></div><div><h3>Conclusions</h3><div>This study demonstrates high hemolysis rates for whole blood potassium samples measured by blood gas analyzers, particularly for the emergency department setting and capillary specimens. This study demonstrates the importance of hemolysis detection for improving laboratory quality and patient safety.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"138 ","pages":"Article 110955"},"PeriodicalIF":2.5,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144230831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A mixed methods service improvement project to investigate the motivational reasons why swab and urine samples are sent for microbiological analysis","authors":"Eilidh Margaret Brown ,&nbsp;Malabika Ghosh ,&nbsp;Victoria Heath ,&nbsp;Sumantra Mukerji ,&nbsp;Robert J. Shorten","doi":"10.1016/j.clinbiochem.2025.110953","DOIUrl":"10.1016/j.clinbiochem.2025.110953","url":null,"abstract":"<div><h3>Background</h3><div>Excessive urine and swab sampling has a direct impact on environmental health, resource availability, sample turnaround time and patient care. Positive cultures from unnecessary samples can lead to inappropriate antimicrobial use and a cascade of further investigations. This project aims to identify the motivational reasons behind swab and urine sample requests in the hospital and community setting, with the aim of reducing unnecessary testing.</div></div><div><h3>Methods</h3><div>A mixed methods approach using a survey followed by qualitative interviews was used. A 16–part online questionnaire was distributed among various health care professionals in primary and secondary care. Upon completion participants were offered the opportunity to volunteer to participate in structured follow up interviews. A number of participants were selected for qualitative interviews.</div></div><div><h3>Results</h3><div>Eighty eight participants completed the questionnaire and five were interviewed. Both the questionnaire and interviews highlighted a wide diversity in the practice of how and why swabs and urine samples are submitted for microbiological analysis. The interviews yielded many ideas for improvements to practice including training and protocol recommendations.</div></div><div><h3>Conclusion</h3><div>The results show a lack of clarity with regards to the primary responsibility for requesting samples. The study identified that this decision is often based on clinical experience, rather than protocol. The time at which a sample is reviewed and treatment, for example antibiotics, is started can vary among the healthcare professionals. Interview participants expressed a need for training, so long as this was tailored to different specialties’ patient populations.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"138 ","pages":"Article 110953"},"PeriodicalIF":2.5,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating plasma RNY1 as a potential biomarker of breast cancer: a case-control study","authors":"Raghda Saad Zaghloul Taleb ,&nbsp;Pacint Elsayed Moez ,&nbsp;Marwa Ibrahim Khedr ,&nbsp;Yasmine Nagy Elwany ,&nbsp;Mohamed Hussein Sultan ,&nbsp;Eman Magdy Omar ,&nbsp;Reham Fadl Moftah","doi":"10.1016/j.clinbiochem.2025.110954","DOIUrl":"10.1016/j.clinbiochem.2025.110954","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer (BC) is the most common cancer in women globally, with early detection playing a crucial role in improving treatment outcomes and survival rates. There is an urgent need for novel biomarkers to aid in early diagnosis, prognosis, and treatment prediction. YRNAs, small non-coding RNAs, have been explored as biomarkers in various cancers, but their role in BC remains under-investigated. This study aimed to explore the expression of circulating plasma YRNAs in BC patients and evaluate their potential as diagnostic and prognostic biomarkers.</div></div><div><h3>Methods</h3><div>Plasma samples were collected from 50 BC patients and 50 age-matched healthy controls. The expression levels of four YRNAs (RNY1, RNY3, RNY4, and RNY5) were measured using quantitative real-time PCR. We also examined the association between YRNA expression and TNM staging, along with their predictive value for disease-free survival.</div></div><div><h3>Results</h3><div>RNY1 was significantly upregulated in BC patients compared to healthy controls, while RNY3, RNY4, and RNY5 did not show significant differences. The area under the receiver operating characteristic curve (AUC) for RNY1 was 0.816 (95% CI: 0.732–0.901), demonstrating good discriminatory power. High RNY1 expression correlated with advanced TNM stage and poor prognosis. Additionally, RNY1 expression predicted disease-free survival, as shown by Kaplan-Meier and univariate Cox regression analyses.</div></div><div><h3>Conclusion</h3><div>The altered expression of RNY1 in BC patients is associated with advanced TNM stage and poor prognosis, suggesting its potential as a diagnostic and prognostic biomarker in BC.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"138 ","pages":"Article 110954"},"PeriodicalIF":2.5,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving laboratory stewardship through benchmarking: A focus on thyroid function tests ordering","authors":"Ka Keung Chan ,&nbsp;Suhhyun Kim ,&nbsp;Patrick C. Mathias ,&nbsp;Jane Dickerson ,&nbsp;Hsuan-Chieh Liao","doi":"10.1016/j.clinbiochem.2025.110952","DOIUrl":"10.1016/j.clinbiochem.2025.110952","url":null,"abstract":"<div><h3>Objectives</h3><div>Thyroid function tests, particularly thyroid-stimulating hormone (TSH) and free thyroxine (fT4), are among the most frequently ordered laboratory tests. This study evaluates longitudinal trends in thyroid testing utilization, assesses the impact of TSH-first reflex testing, and examines specialty-specific differences in test ordering patterns under the PLUGS (Patient-Centered Laboratory Utilization Guidance Services) benchmarking guidelines.</div></div><div><h3>Methods</h3><div>We analyzed TSH and fT4 test volumes from the year 2009 to 2023. A TSH reflex algorithm, which automatically orders fT4 following an abnormal TSH, was implemented in 2016. The metrics were evaluated using the TSH to fT4 ratio (TSH/fT4) and the percentage of fT4 tests associated with abnormal TSH. Specialty-specific differences were assessed by categorizing providers’ specialty, comparing benchmark patterns and diagnostic codes.</div></div><div><h3>Results</h3><div>Both TSH and fT4 testing volume increased significantly from 2009 to 2023. After the implementation of TSH-first reflex algorithm, TSH/fT4 stabilized (∼3.7) and the percentage of fT4 tests associated with abnormal TSH increased significantly from 26 % to 39 %. Providers from primary care demonstrated stronger adherence to the reflex testing, whereas endocrinology and oncology required more tailored approaches.</div></div><div><h3>Conclusions</h3><div>This first longitudinal analysis of thyroid testing under the PLUGS benchmark guidelines highlights improved efficiency following reflex test implementation, though specialty-specific differences persist. Consensus-based benchmarks and laboratory stewardship initiatives further enhance test utilization efficiency, optimize workflow, and ensure appropriate thyroid function testing across diverse clinical settings.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"138 ","pages":"Article 110952"},"PeriodicalIF":2.5,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144139027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing minimal request intervals for laboratory tests: a utilization management study across eight hospitals in South Iran","authors":"Babak Shirazi Yeganeh ,&nbsp;Zahra Rabet ,&nbsp;Zahra Afsar ,&nbsp;Sanaz Amiri ,&nbsp;Alireza Ahmadkhani ,&nbsp;Abdolkhalegh Keshavarzi ,&nbsp;Farhad Lotfi","doi":"10.1016/j.clinbiochem.2025.110948","DOIUrl":"10.1016/j.clinbiochem.2025.110948","url":null,"abstract":"<div><h3>Introduction</h3><div>Effective utilization management in medical laboratories is a challenge. To address this, strategies such as clinical guidelines, minimum requesting intervals (MRIs), and test request limits integrated into hospital information system (HIS) have been proposed.</div></div><div><h3>Materials and methods</h3><div>A guideline was developed to establish MRIs for 15 high-demand laboratory tests in collaboration with an expert panel. It was implemented across eight public hospitals, affiliated with Shiraz University of Medical Sciences, Shiraz, southern Iran. Following institutional approval, the HIS was programmed to notify healthcare providers of deviations from guideline. Several metrics, including requested test counts, hospitalized patient counts, and total hospitalization days, were extracted from the HIS for one year pre- and post-intervention. Then, rates of change in test utilization and associated financial savings were calculated.</div></div><div><h3>Results</h3><div>A total of 414,475 unnecessary tests were averted during the first post-intervention year. In addition, a 12.26% decrease was observed in the test-to-hospitalization-day ratio. The highest decreases obtained for serum calcium (25.87%), serum albumin (22.17%), and alanine aminotransferase (21.03%) testing.</div></div><div><h3>Conclusion</h3><div>Implementing MRI guidelines into the HIS to flag deviations is an effective strategy for laboratory utilization management. Its benefits are multi-faceted, including financial savings (decreased patient and insurer costs), clinical advantages (minimizing diagnostic ambiguity and patient mismanagement), and optimized laboratory resource allocation (staff workload, instrument usage, reagent efficiency).</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"138 ","pages":"Article 110948"},"PeriodicalIF":2.5,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosing protein S deficiency − Navigating challenges","authors":"Rasmus Søgaard Hansen ,&nbsp;Peter H. Nissen ,&nbsp;Julie Brogaard Larsen ,&nbsp;Mustafa Vakur Bor","doi":"10.1016/j.clinbiochem.2025.110950","DOIUrl":"10.1016/j.clinbiochem.2025.110950","url":null,"abstract":"<div><h3>Objective</h3><div>Describe challenges in diagnosing protein S deficiency.</div></div><div><h3>Methods</h3><div>A women in her late 20 s and pregnant in third trimester (G1P0) suffered non-hemorrhagic adrenal infarction. Thrombophilia testing was performed five months post-partum and included analyses for the factor V Leiden (FVL; NM_000130:c.1601G &gt; A; rs6025) and prothrombin c.20210G &gt; A (NM_000506:c.*97G &gt; A; rs1799963) variants, and measurement of antiphospholipid antibodies, protein C (PC) activity and antigen, protein S (PS) activity and antigen, and antithrombin. Initial testing suggested PS deficiency of unknown type. Therefore, targeted genetic screening of the <em>PROS1</em> gene was performed using Sanger sequencing and multiplex ligation-dependent probe amplification to rule out large structural DNA rearrangements, along with repeated thrombophilia testing.</div></div><div><h3>Results</h3><div>The first round of thrombophilia testing found low PS and PC, and heterozygosity for the FVL variant. FVL is known to falsely reduce PS activity up to 15 %, but not influence antigen assays (free and total PS levels). A <em>PROS1</em> variant was identified (c.698G &gt; A; p.(Arg233Lys)), but as this is relatively common, we classified the variant as likely benign. The final round of thrombophilia testing was performed 8 months after the first, and showed normal PC activity, normal PS total, PS free at the lower normal threshold and low PS activity.</div></div><div><h3>Conclusion</h3><div>The patient does not meet the criteria for PS deficiency based on either coagulation assays or <em>PROS1</em> gene genotyping. This case highlights the necessity for clear guidelines to define the role of <em>PROS1</em> genetic testing in routine clinical practice.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"138 ","pages":"Article 110950"},"PeriodicalIF":2.5,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choosing Wisely Canada recommendations for clinical biochemistry: test ordering for sustainable and high-quality patient care","authors":"Daniel R. Beriault ,&nbsp;Yu Chen ,&nbsp;Paul Yip ,&nbsp;Ivan Blasutig ,&nbsp;Vipin Bhayana ,&nbsp;Angela C. Rutledge ,&nbsp;Michelle Parker ,&nbsp;David Kinniburgh ,&nbsp;Dylan Thomas ,&nbsp;Penny Colbourne ,&nbsp;Loralie Langman ,&nbsp;Sarah R. Delaney ,&nbsp;Melissa Bennett ,&nbsp;Curtis Oleschuk ,&nbsp;Yun Huang ,&nbsp;Karina Rodriguez-Capote ,&nbsp;Kristin Hauff ,&nbsp;Danijela Konforte ,&nbsp;Jay Kalra ,&nbsp;Ihssan Bouhtiauy ,&nbsp;Saranya Arnoldo","doi":"10.1016/j.clinbiochem.2025.110951","DOIUrl":"10.1016/j.clinbiochem.2025.110951","url":null,"abstract":"<div><div>Laboratory Medicine is growing at a rapid rate in both the breadth of unique tests and the total number of tests performed per year. Inappropriate overutilization of laboratory tests can lead to patient harm, excessive environmental waste and increased carbon emissions. A focus on reducing inefficiencies in healthcare is needed to ensure a robust and sustainable healthcare system. To promote laboratory sustainability, the Canadian Society of Clinical Chemists (CSCC) has developed ten recommendations related to medical tests within clinical biochemistry. These recommendations are designed as ‘low-hanging fruit’ that should be adopted by both hospital and community laboratories. By implementing automated strategies and/or educational approaches to reduce misuse of laboratory resources, clinical laboratories can move toward a more sustainable model that improves patient care. This list of recommendations, created for Choosing Wisely Canada, covers tests for diabetes, celiac disease, monoclonal gammopathies, iron disorders, liver disorders, kidney disorders, substance use disorders, and allergen testing.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"138 ","pages":"Article 110951"},"PeriodicalIF":2.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wide-range and high-throughput quantification of anamorelin in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry","authors":"Takahiro Sumimoto,&nbsp;Ryota Tanaka,&nbsp;Ayaka Sato,&nbsp;Ryosuke Tatsuta,&nbsp;Hiroki Itoh","doi":"10.1016/j.clinbiochem.2025.110949","DOIUrl":"10.1016/j.clinbiochem.2025.110949","url":null,"abstract":"<div><h3>Objective</h3><div>Cancer cachexia is characterized by weight loss, muscle mass loss, and reduced food intake. Anamorelin is a ghrelin receptor agonist approved for the treatment of cancer cachexia. In this study, we established and validated an assay for quantification of anamorelin in human plasma.</div></div><div><h3>Methods</h3><div>For quantification of anamorelin, samples were pretreated with solid-phase extraction and analyzed by ultra-high performance liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS). This analytical method was validated in accordance with the Food and Drug Administration (FDA) bioanalytical method validation guidance. We used the established assay to quantify plasma anamorelin concentrations in five patients with cancer cachexia treated with anamorelin.</div></div><div><h3>Results</h3><div>The validation results of this assay method met the acceptance criteria recommended by the FDA guidance. Within-batch and batch-to-batch precision at the lower limit of quantification and three quality control levels were within 6.20 % and 6.55 % coefficient of variation, respectively. Within-batch and batch-to-batch accuracies ranged from −2.58 to −1.33 % and −3.78 to −1.69 %, respectively. Recovery rates and matrix effects corrected by internal standard were 82.7–84.2 % and 102.7–104.6 %, respectively. Using the established assay with a calibration range of 0.1–2500 ng/mL, plasma anamorelin concentrations were successfully quantified in all 15 plasma samples from 5 patients with cancer cachexia.</div></div><div><h3>Conclusions</h3><div>We established and validated a method to measure plasma anamorelin concentrations using UHPLC/MS-MS combined with SPE, and successfully applied the novel method to measure plasma anamorelin concentrations in patients with cancer cachexia. By measuring plasma anamorelin concentrations in large scale studies, the established quantitative method is expected to contribute to the pharmacokinetic study of anamorelin.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"138 ","pages":"Article 110949"},"PeriodicalIF":2.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustainable healthcare and medical laboratories: The impact of global collaborations between frameworks and initiatives","authors":"Fikriye Uras","doi":"10.1016/j.clinbiochem.2025.110945","DOIUrl":"10.1016/j.clinbiochem.2025.110945","url":null,"abstract":"<div><div>Climate change is a pressing global challenge that requires urgent action. The Paris Agreement and the 2030 Agenda of United Nations (UN) set clear global targets for emission reduction and sustainability to limit warming to 1.5 °C. Partnerships between standardization organizations are crucial in accelerating climate action. The Geneva Sustainability Centre (GSC) is at the forefront of healthcare sustainability, launching the Sustainability Accelerator Tool (SAT) in 2023 to help hospitals assess their environmental impact. In partnership with GSC, Joint Commission International (JCI) has integrated sustainability into its accreditation standards and will introduce the JCI-GSC Healthcare Sustainability Certification in 2025, built on the SAT. To accelerate the achievement of the Sustainable Development Goals (SDGs), ISO and the UN formed a strategic partnership in 2023 to create the first global SDG standard. ISO has published the IWA 42:2022 Net Zero Guidelines and is developing its first global Standard on Net Zero, set for release in 2025. Additionally, ISO introduced the Climate Change Amendments, embedding climate considerations into over 30 existing management system standards, including ISO 9001. With these amendments now shaping all newly developed or revised standards, future updates to ISO 15189 will likely incorporate sustainability requirements, especially as ISO 9001 is an essential part of ISO 15189. Reducing operational emissions from healthcare and medical laboratories alone will not achieve net zero. A sector-wide approach is essential, tackling supply chain emissions from energy, pharmaceuticals, and medical devices. Combating climate change requires a coordinated, cross-sector effort, making international collaboration indispensable. This review highlights key global frameworks, standards, guidelines, and initiatives that have evolved through collaboration to help healthcare organizations, including medical laboratories, to advance sustainability and climate resilience.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"138 ","pages":"Article 110945"},"PeriodicalIF":2.5,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The comparison of miRNA expression levels in Type 2 diabetes and diabetic peripheral neuropathy patients","authors":"Aleyna Ayaz ,&nbsp;Sibel Kuras ,&nbsp;Bekir Erdogan ,&nbsp;Hanife Serife Aktas ,&nbsp;Mahmud Esad Pence ,&nbsp;Halime Hanim Pence","doi":"10.1016/j.clinbiochem.2025.110946","DOIUrl":"10.1016/j.clinbiochem.2025.110946","url":null,"abstract":"<div><h3>Objectives</h3><div>We aimed to investigate the correlation between miRNA expression levels in patients with type 2 diabetes mellitus (T2DM) and diabetic peripheral neuropathy (DPN) and determine their potential functions in DPN.</div></div><div><h3>Material and Methods</h3><div>The study participants were between 30 and 75 years old and divided into three groups: 30 patients with Type 2 T2DM without DPN (group 1), 30 patients with DPN (group 2), and 30 healthy controls (group 3). Whole blood samples were obtained from the individuals forming the groups, and the expression of the miR-128a, miR-146a, miR-155, and miR-375 genes in these samples was determined by real-time polymerase chain reaction (PCR). RNU6 was used as the housekeeping gene.</div></div><div><h3>Results</h3><div>No significant differences were observed in the expression levels of miR-128a, miR-146a, and miR-155 among all groups (p &gt; 0.05). However, miR-375 expression levels differed significantly between the group 2 and the group 3 (p &lt; 0.05). No significant differences in miR-375 expression levels were found between the group 1 and the group 3, nor between the group 1 and the group 2 (p &gt; 0.05).</div></div><div><h3>Conclusions</h3><div>miR-375 may be linked to the progression of diabetic peripheral neuropathy (DPN).</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"138 ","pages":"Article 110946"},"PeriodicalIF":2.5,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}